GlobeNewswire by notified

Resolutions of Harvia Plc's Annual General Meeting on 26 April 2024

Share

STOCK EXCHANGE RELEASE

26 April 2024 at 1.30 p.m. EEST

Resolutions of Harvia Plc's Annual General Meeting on 26 April 2024

Harvia Plc’s Annual General Meeting, held today on 26 April 2024, approved the financial statements and discharged the members of the Board of Directors and the company’s CEO from liability for the financial year 2023. The Annual General Meeting approved in an advisory decision the remuneration report for governing bodies. The Annual General Meeting resolved to reject the revised remuneration policy for the company’s governing bodies. The resolution made is advisory.

Use of the profit shown on the balance sheet and the distribution of dividend

The Annual General Meeting approved the Board of Directors’ proposal that EUR 0.68 per share be paid as dividend and that the remainder of the distributable funds be transferred to shareholders’ equity.

The dividend is paid in two instalments. The first instalment, EUR 0.34 per share, will be paid to shareholders who are registered in the shareholders’ register maintained by Euroclear Finland Ltd on the record date of the dividend of 30 April 2024. This instalment of the dividend will be paid on 8 May 2024.

The second instalment, EUR 0.34 per share, will be paid in October 2024. The second instalment will be paid to shareholders who are registered in the shareholders’ register maintained by Euroclear Finland Ltd on the record date of the dividend, which, together with the dividend payment date, shall be decided by the Board of Directors in its meeting scheduled for 17 October 2024. The record date of the dividend date would then be 21 October 2024 and the dividend payment date 28 October 2024.

The Board of Directors and the Auditor

The Annual General Meeting resolved that the Board of Directors consists of six members. Olli Liitola, Anders Holmén, Hille Korhonen, Heiner Olbrich, Markus Lengauer and Catharina Stackelberg-Hammarén were re-elected to the Board of Directors.

It was resolved that a monthly remuneration of the members of the Board of Directors is paid as follows: The Chair of the Board of Directors is paid EUR 5,000, Deputy Chair of the Board is paid EUR 3,500 (provided a Deputy Chair is elected) and members of the Board of Directors are each paid EUR 3,000. Additionally, the remuneration of the Board committee members is paid as meeting fees instead of a monthly fee as follows: EUR 1,000 per meeting for the chair of the committee and EUR 600 per meeting for the other members.

Further, the monthly remuneration of the Board members will be paid in company shares and in cash in such a way that 40 per cent of the total monthly remuneration will be paid in company shares purchased at a price determined in public trading on Nasdaq Helsinki Ltd and 60 per cent will be paid in cash. The shares will be acquired within two weeks from the day following the publication of the company’s interim report for the period 1 January–31 March 2024. The company will pay any costs and transfer tax related to the purchase of company shares. In case the remuneration cannot be paid in company shares due to legal or other regulatory restrictions or due to other reasons related to the company or a member of the Board of Directors, the remuneration will be paid in cash.

A member of the Board of Directors may not transfer the shares received as remuneration for Board membership in 2024 until two years have passed since the date of transfer of the shares.

The remuneration for the Board committee work will be paid fully in cash.

The members of Board of Directors who live outside Finland will be paid EUR 900 for each meeting if the member travels to Finland only for that meeting. The fee will be paid in cash. When the member of Board of Directors attends the meeting by telephone or other electronic means, no fee will be paid for that meeting. No fee is paid for decisions made without convening a meeting.

The travel expenses of the members of the Board of Directors are compensated in accordance with the company’s travel rules.

Authorised Public Accounting firm Deloitte Oy was elected as the Auditor of the company and as a certification authority for the company's sustainability reporting in financial year 2024 and Authorised Public Accountant Johan Groop will act as the Responsible Auditor. It was resolved that the remuneration for the Auditor is paid according to the Auditor’s reasonable invoice.

Authorising the Board of Directors to decide on the repurchase of the company’s own shares

The Board of Directors was authorised to resolve on the repurchase of a maximum of 934,711 shares in the company in one or several tranches. The maximum number of shares to be repurchased represents approximately 5% of all the shares in the company on the date of the Annual General Meeting. Only the unrestricted equity of the company can be used to repurchase own shares on the basis of the authorisation.

The shares can be repurchased otherwise than in proportion to the shareholdings of the shareholders in public trading arranged by Nasdaq Helsinki Oy for the market price formed at the moment of purchase or otherwise at a price formed on the market. The authorisation may be used e.g. for the purposes of the company’s share-based incentive systems, for the purposes of board compensation and other matters decided by the Board of Directors. The Board of Directors is authorised to decide on all other matters related to the repurchasing of shares.

The authorisation replaces the authorisation of the Board of Directors to resolve on the repurchase of own shares granted by the shareholders of the company on 20 April 2023. The authorisation is valid until the closing of the next Annual General Meeting, but no longer than until 30 June 2025.

Authorising the Board of Directors to decide on the issue of shares, options and other special rights entitling to shares

The Annual General Meeting authorised the Board of Directors to decide on the issuance of shares and the issuance of special rights entitling to shares as referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act in one or several tranches, either against payment or without payment. The aggregate number of shares to be issued, including the shares to be received based on special rights, must not exceed 1,869,423 shares. The Board of the Directors may resolve to issue new shares or to transfer own shares possibly held by the company.

The authorisation entitles the Board of Directors to decide on all other matters related to the issuance of shares and special rights entitling to shares, including the right to deviate from the pre-emptive right of shareholders to subscribe to shares to be issued. The authorisation may be used for the purposes of strengthening the balance sheet and financing position of the company, for the purposes of board compensation or for other purposes decided by the Board of Directors.

The authorisation is valid until the closing of the next Annual General Meeting, but no longer than until 30 June 2025. The authorisation replaces and revokes all previous unused authorisations of the Board of Directors to resolve on the issuance of shares, share options and other special rights entitling to shares.

The minutes of the Annual General Meeting will be available on the company’s website www.harviagroup.com on 10 May 2024 at the latest.

HARVIA PLC

For further information

CEO Matias Järnefelt, tel. +358 40 5056 080

CFO Ari Vesterinen, tel +358 40 505 0440

Distribution:

Nasdaq Helsinki Oy

Main media

www.harviagroup.com

Harvia in short

Harvia is one of the leading companies operating in the sauna and spa market globally, as measured by revenue. Harvia’s brands and product portfolio are well known in the market, and the company’s comprehensive product portfolio strives to meet the needs of the international sauna and spa market of both private and professional customers.

Harvia’s revenue totaled EUR 150.5 million in 2023. Harvia Group employs approximately 600 professionals in Finland, Germany, United States, Romania, China and Hong Kong, Austria, Italy, Estonia, and Sweden. The company is headquartered in Muurame, Finland, adjacent to its largest sauna and sauna component manufacturing facility.

Read more: https://harviagroup.com


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Epiq Service Cloud Delivers Legal Workflow Gen AI Text Summarization6.5.2024 15:22:30 CEST | Press release

Advanced AI is accessible without the need for specialized AI knowledge NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Epiq, a global technology-enabled leader to the legal industry and corporations, today announced Gen AI Text Summarization within the Epiq Service Cloud. This latest feature, powered by Azure OpenAI Service, is adaptable and scalable to support a wide range of legal processes, including eDiscovery and investigations, deposition summaries, mediations, and trials. “Our Gen AI Text Summarization feature underscores Epiq’s commitment to making advanced technology accessible and practical for every legal professional without specialized AI knowledge,” said Eric Crawley, Senior Vice President, Legal Solutions at Epiq. “This feature brings efficiencies to a diverse set of legal workflows while maintaining high standards of accuracy.” The latest Gen AI advancement simplifies the review of complex documents to aid in early case assessment and enhance data analysis. Legal profession

Schouw & Co. aktietilbagekøbsprogram, uge 18 20246.5.2024 15:11:08 CEST | pressemeddelelse

Den 4. marts 2024 iværksatte Schouw & Co. et aktietilbagekøbsprogram som beskrevet i selskabsmeddelelse nr. 13 af 1. marts 2024. I henhold til programmet vil Schouw & Co. i perioden fra 4. marts 2024 til 31. december 2024 købe egne aktier for et maksimalt beløb på 200 mio. kr. Aktietilbagekøbsprogrammet gennemføres i henhold til Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 om markedsmisbrug (MAR) og Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016 ("Safe Harbour”-reglerne). HandelsdagAntal aktierGennemsnitlig kursBeløb Akkumuleret indtil 26/4 2024 79.600 526,89 41.940.547 mandag 29. april 2024 1.900 529,73 1.006.487 tirsdag 30. april 2024 1.000 539,39 539.390 onsdag 1. maj 2024 1.000 555,04 555.040 torsdag 2. maj 2024 1.000 556,37 556.370 fredag 3. maj 2024 1.200 556,39 667.668 I perioden 29/4 2024 - 3/5 2024 6.100 545,07 3.324.955 Samlet i perioden 4/3 2024 - 3/5 2024 85.700 528,19 45.265.502 Ved periodens udløb ejer Schouw & Co. 2.19

Schouw & Co. share buy-back programme, week 18 20246.5.2024 15:11:08 CEST | Press release

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Trading dayNo. of sharesAverage priceAmount Accumulated until 26/4/2024 79,600 526.89 41,940,547 Monday, 29 April 2024 1,900 529.73 1,006,487 Tuesday, 30 April 2024 1,000 539.39 539,390 Wednesday, 1 May 2024 1,000 555.04 555,040 Thursday, 2 May 2024 1,000 556.37 556,370 Friday, 3 May 2024 1,200 556.39 667,668 In the period 29/4/2024 - 3/5/2024 6,100 545.07 3,324,955 Accumulated 4/3/2024 - 3/5/2024 85,700 528.19 45,265,502 Following the above transactions Schouw & Co. holds a

AKVA group ASA: Status buyback of own shares6.5.2024 14:57:37 CEST | Press release

As announced on 22 March 2024 AKVA group ASA ("AKVA group" or the "Company") has initiated repurchase of up to 200,000 of the company's own shares to be used in its share programme for employees. From 30 April through 6 May the company bought 10 855 shares at an weighted average price of NOK 65,8477. See the attached documents for detailed information about the transactions made. The company has bought a total of 57 896 shares at an weighted average price of NOK 68,3271 since 22 March. After these transactions, the company owns 288 559 treasury shares. This information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052 and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Dated: 6 May 2024 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagrou

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as

HiddenA line styled icon from Orion Icon Library.Eye